- 专利标题: Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
-
申请号: US16270206申请日: 2019-02-07
-
公开(公告)号: US10369143B2公开(公告)日: 2019-08-06
- 发明人: Eric Elenko , Philip E. Murray, III , Andrew C. Miller
- 申请人: PureTech Health LLC
- 申请人地址: US MA Boston
- 专利权人: PureTech Health LLC
- 当前专利权人: PureTech Health LLC
- 当前专利权人地址: US MA Boston
- 代理机构: Global Patent Group, LLC
- 代理商 Dennis A. Bennet; Clifford A. Schlecht
- 主分类号: A61K31/46
- IPC分类号: A61K31/46 ; A61K9/48 ; A61K31/4439 ; A61K31/138 ; A61K31/222 ; A61K31/4025 ; A61K31/4178 ; A61K31/438 ; A61K31/44 ; A61K31/4725 ; A61K45/06
摘要:
Provided herein is a method of treating a central nervous system disorder in a patient in need thereof, wherein the central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia. The method comprises orally administering an initial dose of between 75 mg and 300 mg xanomeline and an initial dose of between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. Provided that the patient tolerates said administration, an increased dose of trospium chloride and an increased dose of xanomeline are orally administering to the patient, wherein the increased dose of trospium chloride is greater than the initial dose of the trospium chloride, and wherein the increased dose of xanomeline is greater than the initial dose of the xanomeline.
公开/授权文献
信息查询